Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.82 [0.68, 0.99] | | < 1 | | 0% | 1 study (1/-) | 97.8 % | NA | not evaluable | | crucial | - |
progression or deaths (PFS) | 0.84 [0.70, 1.01] | | < 1 | | 0% | 1 study (1/-) | 96.9 % | NA | not evaluable | | important | - |
objective responses (ORR) | 1.02 [0.72, 1.44] | | > 1 | | 0% | 1 study (1/-) | 54.5 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE (any grade) | 4.09 [0.86, 19.46] | | < 1 | | 0% | 1 study (1/-) | 3.9 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 1.05 [0.74, 1.49] | | < 1 | | 0% | 1 study (1/-) | 39.4 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 1.89 [0.98, 3.64] | | < 1 | | 0% | 1 study (1/-) | 2.9 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (any grade) | 2.63 [1.59, 4.36] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
STRAE (any grade) | 1.45 [0.96, 2.20] | | < 1 | | 0% | 1 study (1/-) | 3.8 % | NA | not evaluable | | non important | - |
STRAE (grade 3-4) | 1.28 [0.83, 1.98] | | < 1 | | 0% | 1 study (1/-) | 13.4 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 1.04 [0.59, 1.84] | | < 1 | | 0% | 1 study (1/-) | 44.2 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 1.15 [0.81, 1.61] | | < 1 | | 0% | 1 study (1/-) | 21.7 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 6.24 [1.38, 28.14] | | < 1 | | 0% | 1 study (1/-) | 0.9 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (any grade) | 3.75 [1.97, 7.16] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (grade 3-4) | 7.10 [2.44, 20.63] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Adrenal insufficiency TRAE (grade 3-4) | 6.06 [0.30, 121.51] | | < 1 | | 0% | 1 study (1/-) | 12.2 % | NA | not evaluable | | non important | - |
Alopecia TRAE (grade 3-4) | 0.25 [0.01, 5.54] | | < 1 | | 0% | 1 study (1/-) | 80.7 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 0.68 [0.40, 1.15] | | < 1 | | 0% | 1 study (1/-) | 92.6 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 1.51 [0.25, 9.08] | | < 1 | | 0% | 1 study (1/-) | 32.8 % | NA | not evaluable | | non important | - |
Constipation TRAE (grade 3-4) | 2.00 [0.07, 59.99] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 2.01 [0.18, 22.28] | | < 1 | | 0% | 1 study (1/-) | 28.7 % | NA | not evaluable | | non important | - |
Diabetes TRAE (grade 3-4) | 4.02 [0.18, 89.63] | | < 1 | | 0% | 1 study (1/-) | 19.3 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 3.57 [0.73, 17.33] | | < 1 | | 0% | 1 study (1/-) | 5.8 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 0.66 [0.11, 4.01] | | < 1 | | 0% | 1 study (1/-) | 67.2 % | NA | not evaluable | | non important | - |
Febrile neutropenia TRAE (grade 3-4) | 0.69 [0.32, 1.48] | | < 1 | | 0% | 1 study (1/-) | 82.9 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 2.00 [0.07, 59.99] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
Hypophysitis TRAE (grade 3-4) | 2.00 [0.07, 59.99] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 4.02 [0.18, 89.63] | | < 1 | | 0% | 1 study (1/-) | 19.3 % | NA | not evaluable | | non important | - |
Increased lipase level TRAE (grade 3-4) | 5.08 [0.59, 43.75] | | < 1 | | 0% | 1 study (1/-) | 7.1 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 1.08 [0.51, 2.28] | | < 1 | | 0% | 1 study (1/-) | 42.4 % | NA | not evaluable | | non important | - |
Myocarditis TRAE (grade 3-4) | 2.00 [0.07, 59.99] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.60 [0.14, 2.52] | | < 1 | | 0% | 1 study (1/-) | 75.9 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.92 [0.64, 1.32] | | < 1 | | 0% | 1 study (1/-) | 68.0 % | NA | not evaluable | | non important | - |
Paraesthesia TRAE (grade 3-4) | 2.00 [0.07, 59.99] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 3.02 [0.31, 29.25] | | < 1 | | 0% | 1 study (1/-) | 17.1 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 1.00 [0.02, 50.59] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 6.06 [0.30, 121.51] | | < 1 | | 0% | 1 study (1/-) | 12.2 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 0.91 [0.50, 1.67] | | < 1 | | 0% | 1 study (1/-) | 62.1 % | NA | not evaluable | | non important | - |
Thyroiditis TRAE (grade 3-4) | 1.00 [0.02, 50.59] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 1.00 [0.14, 7.15] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
Alopecia AE (grade 3-4) | 0.50 [0.04, 5.53] | | < 1 | | 0% | 1 study (1/-) | 71.3 % | NA | not evaluable | | non important | - |
Anaemia AE (grade 3-4) | 0.67 [0.41, 1.07] | | < 1 | | 0% | 1 study (1/-) | 95.3 % | NA | not evaluable | | non important | - |
Asthenia AE (grade 3-4) | 1.68 [0.40, 7.10] | | < 1 | | 0% | 1 study (1/-) | 24.1 % | NA | not evaluable | | non important | - |
Back pain AE (grade 3-4) | 0.50 [0.02, 14.94] | | < 1 | | 0% | 1 study (1/-) | 65.4 % | NA | not evaluable | | non important | - |
Constipation AE (grade 3-4) | 2.00 [0.07, 59.99] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
Cough AE (grade 3-4) | 2.00 [0.07, 59.99] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
Decreased appetite AE (grade 3-4) | 2.53 [0.49, 13.15] | | < 1 | | 0% | 1 study (1/-) | 13.6 % | NA | not evaluable | | non important | - |
Diarrhoea AE (grade 3-4) | 2.37 [0.61, 9.26] | | < 1 | | 0% | 1 study (1/-) | 10.8 % | NA | not evaluable | | non important | - |
Dyspnoea AE (grade 3-4) | 1.51 [0.42, 5.42] | | < 1 | | 0% | 1 study (1/-) | 26.3 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 1.00 [0.20, 5.00] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
Febrile neutropenia AE (grade 3-4) | 0.81 [0.39, 1.69] | | < 1 | | 0% | 1 study (1/-) | 71.0 % | NA | not evaluable | | non important | - |
Headache AE (grade 3-4) | 2.00 [0.07, 59.99] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
Hypertension AE (grade 3-4) | 7.16 [0.88, 58.62] | | < 1 | | 0% | 1 study (1/-) | 3.4 % | NA | not evaluable | | non important | - |
Hyperthyroidism AE (grade 3-4) | 2.00 [0.07, 59.99] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
Increased Lipase Level AE (grade 3-4) | 1.51 [0.42, 5.42] | | < 1 | | 0% | 1 study (1/-) | 26.3 % | NA | not evaluable | | non important | - |
Leucopenia AE (grade 3-4) | 0.92 [0.43, 2.01] | | < 1 | | 0% | 1 study (1/-) | 57.8 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 1.00 [0.29, 3.50] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
Neutropenia AE (grade 3-4) | 0.95 [0.66, 1.37] | | < 1 | | 0% | 1 study (1/-) | 60.9 % | NA | not evaluable | | non important | - |
Pneumonia AE (grade 3-4) | 1.00 [0.39, 2.56] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
Pruritus AE (grade 3-4) | 1.00 [0.02, 50.59] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
Pyrexia AE (grade 3-4) | 0.50 [0.02, 14.94] | | < 1 | | 0% | 1 study (1/-) | 65.4 % | NA | not evaluable | | non important | - |
Rash AE (grade 3-4) | 6.06 [0.30, 121.51] | | < 1 | | 0% | 1 study (1/-) | 12.2 % | NA | not evaluable | | non important | - |
Thrombocytopenia AE (grade 3-4) | 0.96 [0.53, 1.72] | | < 1 | | 0% | 1 study (1/-) | 56.0 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 1.34 [0.30, 6.04] | | < 1 | | 0% | 1 study (1/-) | 35.3 % | NA | not evaluable | | non important | - |